Kymera Therapeutics (NASDAQ:KYMR) Issues Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Kymera Therapeutics (NASDAQ:KYMR) announced its earnings results on Wednesday. The company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.09, FiscalAI reports. The business had revenue of $65.00 million for the quarter, compared to analyst estimates of $32.78 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The company’s quarterly revenue was up 465.2% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.95) EPS.

Here are the key takeaways from Kymera Therapeutics’ conference call:

• KT-621’s atopic dermatitis Phase IIb trial completed enrollment six months early, with top-line data now expected by year-end 2026 and Phase III initiation targeted for mid-2027. Management believes the oral, once-daily profile could substantially expand systemic treatment in type 2 inflammatory diseases.
• The asthma Phase IIb trial is enrolling and remains on track for top-line results by late 2027, while an open-label extension will provide up to 52 additional weeks of safety and efficacy data. The company also expects KT-579 healthy-volunteer data in Q4 2026 before advancing into lupus proof-of-concept studies.
• Partnered programs continue to advance, including Sanofi’s KT-485 Phase I start, which generated a $20 million milestone, and Gilead’s $45 million option exercise fee. Gilead’s KT-200 is expected to enter clinical development next year.
• Kymera ended June with approximately $1.5 billion in cash and investments and reiterated a cash runway into 2029. Management expects this funding to support current Phase II programs, KT-579 through lupus proof of concept, and the beginnings of KT-621 Phase III development.
• The company recognized all currently deferred collaboration revenue in the second quarter, totaling $65 million, and does not expect additional revenue in 2026 absent new milestones. R&D cash spending rose 22% sequentially to $109.1 million as clinical investment increases.

Kymera Therapeutics Stock Down 0.4%

Shares of Kymera Therapeutics stock traded down $0.47 during trading on Thursday, reaching $105.01. 227,745 shares of the stock were exchanged, compared to its average volume of 737,458. The firm has a market cap of $8.64 billion, a price-to-earnings ratio of -29.44 and a beta of 1.95. Kymera Therapeutics has a 1 year low of $36.65 and a 1 year high of $130.05. The stock’s fifty day moving average is $100.29 and its 200 day moving average is $88.40.

Insider Transactions at Kymera Therapeutics

In other news, Director Bruce Booth sold 31,283 shares of the business’s stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $109.48, for a total transaction of $3,424,862.84. Following the transaction, the director directly owned 461,794 shares of the company’s stock, valued at approximately $50,557,207.12. The trade was a 6.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Nello Mainolfi sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $119.00, for a total value of $5,950,000.00. Following the transaction, the chief executive officer owned 666,568 shares of the company’s stock, valued at approximately $79,321,592. This represents a 6.98% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 3,607,813 shares of company stock worth $387,818,004. Corporate insiders own 15.98% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Los Angeles Capital Management LLC purchased a new stake in shares of Kymera Therapeutics in the 4th quarter worth approximately $153,000. CIBC Asset Management Inc bought a new stake in Kymera Therapeutics in the fourth quarter worth $229,000. Hudson Bay Capital Management LP bought a new stake in Kymera Therapeutics in the second quarter worth $218,000. Oxford Asset Management LLP purchased a new stake in shares of Kymera Therapeutics in the second quarter worth $201,000. Finally, Lazard Asset Management LLC purchased a new stake in shares of Kymera Therapeutics in the second quarter worth $116,000.

Wall Street Analysts Forecast Growth

KYMR has been the topic of several research analyst reports. Wall Street Zen upgraded shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 2nd. Loop Capital set a $97.00 target price on shares of Kymera Therapeutics in a research report on Monday, June 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Friday, July 17th. Truist Financial increased their price target on shares of Kymera Therapeutics from $116.00 to $136.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Finally, Citigroup restated a “buy” rating on shares of Kymera Therapeutics in a research report on Thursday. Twenty investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $124.96.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.